ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXPLORES THE ASPIRATIONAL AND PRACTICAL ELEMENTS OF GENERATING REAL-WORLD EVIDENCE

Published Nov 2, 2016
Vienna, Austria—1 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) hosted an issue panel this afternoon entitled, Real World Evidence to Support Value Proposition and Reimbursement at Launch: The Aspirational Meets the Impractical?, at the Society’s 19th Annual European Congress in Vienna, Austria. The issue panel was moderated by Kari Edwards, PhD, Managing Partner, Harbinger Health, LLC, Los Angeles, CA, USA. Panelists for the session included:
  • Adrian R. Levy, PhD, Professor and Head, Community Health and Epidemiology, Dalhousie University, Nova Scotia, AL, Canada
  • Arie Barlev, PharmD, MS, Senior Director, Health Economics and Outcomes Research, Medivation, Inc., San Francisco, CA, USA
  • Andrew Briggs, DPhil, William R. Lindsay Chair of Health Economics and Professor of Health Economics, University of Glasgow, Glasgow, UK
The panelists explored the tension that exists between the aspirational and practical elements of generating real-world evidence in a timely fashion to support reimbursement for the launch of a new product launch. Kari Edwards, PhD presented a number of illustrative case studies to provide context and moderated the debate. Adrian R. Levy, PhD provided a payer perspective, arguing in favor of real-world evidence and noting that timely assessment of likely effectiveness would support reimbursement submissions upon product launch. Arie Barlev, PharmD, MS presented an industry view noting the practical challenges associated with collecting evidence within a short, post-approval timeframe, and highlighted the problem of selection bias when measuring relative effect in populations exposed to newly approved agents compared with standards of care. The final speaker, Andrew Briggs, DPhil, represented the health economics point of view and demonstrated the use of modeling techniques to exploit the rigorous nature of clinical trial data. Additional information on the ISPOR 19th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORVienna.

###

Related Stories

Landmark Analysis in Value in Health Uncovers Potential Research Efficiency Gains

Sep 15, 2025

Value in Health, the official journal of ISPOR announced the publication of a landmark scoping review that provides a comprehensive mapping of patient preference studies across key medical domains, revealing the first robust evidence base for advancing meta-analyses and benefit transfer methods in healthcare decision-making.

ISPOR Real-World Evidence Summit 28-30 September 2025 | Tokyo, Japan

Sep 9, 2025

ISPOR announced details for its ISPOR Real-World Evidence Summit 2025: Through The Lens of Asia Pacific. The Summit brings together top experts, decision makers, and industry leaders to explore the latest breakthroughs, share cutting-edge research, and discuss innovative solutions to the region’s most pressing healthcare challenges.

"Most-Favored Nation" Drug Pricing Strategy May Backfire, New Research Warns

Sep 3, 2025

Value in Health, the official journal of ISPOR announced the publication of a new analysis suggesting that the Trump Administration's "Most-Favored Nation" approach to lowering US drug prices by referencing international prices may not achieve its intended goals, based on decades of experience with similar policies in Europe.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×